Management of adult vitiligo: approved topical JAK inhibitor and standard therapies.

Maria Elisabetta Greco¹, Francesca Feresin¹, Alberto di Caro¹, Francesca Paola Sasso¹, Ilaria Proietti², Carmen Cantisani¹, Antonio di Guardo^1,3, Luigi Angelo Fiorito⁴, Nicola Perrotta⁴, Giovanni Pellacani¹, Concetta Potenza², Steven Paul Nisticò¹, Annunziata Dattola¹

¹Dermatology Unit, Department of Medical and Cardiovascular Sciences, University La Sapienza of Rome, Italy.

²Unit of Dermatology, Department of Medical-Surgical Science and Biotechnologies, Sapienza University of Rome, A. Fiorini Hospital, Terracina, Latina, Italy.

³IDI-IRCCS, Dermatological Research Hospital, Rome, Italy.

⁴Department of Physiology and Pharmacology "V. Erspamer", Sapienza University, Rome, Italy.

PubMed DOI

Abstract

INTRODUCTION: Vitiligo is a chronic autoimmune depigmenting disorder. Ruxolitinib 1.5% cream is currently the only therapy specifically approved for its treatment. In addition, clinical guidelines recommend off label standard therapies, including topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), phototherapy (narrowband UVB or excimer devices), and selected off-label systemic re…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.